Targeting oncoproteins with a positive selection assay for protein degraders.

Targeting oncoproteins with a positive selection assay for protein degraders.
复制标题

用蛋白质降解物的阳性选择试验靶向癌蛋白。

DOI:
10.1126/sciadv.abd6263
复制
发表时间:
2021-03
期刊:
影响因子:
13.6
通讯作者:
Kaelin WG Jr
Kaelin WG Jr
中科院分区:
综合性期刊1区
文献类型:
--
作者:
Koduri V;Duplaquet L;Lampson BL;Wang AC;Sabet AH;Ishoey M;Paulk J;Teng M;Harris IS;Endress JE;Liu X;Dasilva E;Paulo JA;Briggs KJ;Doench JG;Ott CJ;Zhang T;Donovan KA;Fischer ES;Gygi SP;Gray NS;Bradner J;Medin JA;Buhrlage SJ;Oser MG;Kaelin WG Jr

文献摘要

参考文献

被引文献

相似文献

一种新的阳性选择试验可以提高发现降解以前不可用的蛋白质的化合物。大多数细胞内蛋白质缺乏适于用药物样小分子改变其功能的疏水口袋。最近的研究表明,一些不可药用的蛋白质可以被降解它们的化合物靶向。例如,沙利度胺样药物(IMiD)通过将关键的多发性骨髓瘤转录因子IKZF 1和IKZF 3募集到cereblon E3泛素连接酶来降解它们。目前用于鉴定降解剂的信号损失(“下降”)测定通常表现出差的信噪比、窄的动态范围和来自非特异性抑制转录或翻译的化合物的假阳性。在这里,我们描述了降解剂的信号增益(“上”)测定。在阵列式化学筛选中,我们鉴定了新型IMiD样IKZF 1降解剂和Spaetin-1,与IMiD不同,Spaetin-1以不依赖脑细胞的方式降解IKZF 1。在基于CRISPR-Cas9的合并筛选中,我们发现CDK 2调节ASCL 1致癌转录因子的丰度。这种方法应该有助于鉴定直接或间接降解不可药用蛋白质的药物。
A new positive selection assay could enhance the discovery of compounds that degrade previously undruggable proteins. Most intracellular proteins lack hydrophobic pockets suitable for altering their function with drug-like small molecules. Recent studies indicate that some undruggable proteins can be targeted by compounds that can degrade them. For example, thalidomide-like drugs (IMiDs) degrade the critical multiple myeloma transcription factors IKZF1 and IKZF3 by recruiting them to the cereblon E3 ubiquitin ligase. Current loss of signal (“down”) assays for identifying degraders often exhibit poor signal-to-noise ratios, narrow dynamic ranges, and false positives from compounds that nonspecifically suppress transcription or translation. Here, we describe a gain of signal (“up”) assay for degraders. In arrayed chemical screens, we identified novel IMiD-like IKZF1 degraders and Spautin-1, which, unlike the IMiDs, degrades IKZF1 in a cereblon-independent manner. In a pooled CRISPR-Cas9–based screen, we found that CDK2 regulates the abundance of the ASCL1 oncogenic transcription factor. This methodology should facilitate the identification of drugs that directly or indirectly degrade undruggable proteins.
DOI: 10.1016/j.celrep.2016.06.081
发表时间: 2016-08-02
期刊: Cell reports
影响因子: 8.8
作者:
Borromeo MD;Savage TK;Kollipara RK;He M;Augustyn A;Osborne JK;Girard L;Minna JD;Gazdar AF;Cobb MH;Johnson JE
通讯作者: Johnson JE
抑制细胞周期蛋白依赖性激酶活性会触发小鼠神经母细胞瘤细胞的神经元分化。
DOI: 10.1083/jcb.131.1.227
发表时间: 1995-10
影响因子: 7.8
作者:
KRANENBURG, O;SCHARNHORST, V;VANDEREB, AJ;ZANTEMA, A
通讯作者: ZANTEMA, A
DOI: 10.1002/cmdc.201800271
发表时间: 2018-08-10
期刊: ChemMedChem
影响因子: 3.4
作者:
Burslem GM;Ottis P;Jaime-Figueroa S;Morgan A;Cromm PM;Toure M;Crews CM
通讯作者: Crews CM
Beclin1 通过调节 USP10 和 USP13 的去泛素化活性来控制 p53 的水平。
DOI: 10.1016/j.cell.2011.08.037
发表时间: 2011-09-30
期刊: Cell
影响因子: 64.5
作者:
Liu J;Xia H;Kim M;Xu L;Li Y;Zhang L;Cai Y;Norberg HV;Zhang T;Furuya T;Jin M;Zhu Z;Wang H;Yu J;Li Y;Hao Y;Choi A;Ke H;Ma D;Yuan J
通讯作者: Yuan J
DOI: 10.1038/leu.2012.119
发表时间: 2012-11
期刊: LEUKEMIA
影响因子: 11.4
作者:
Lopez-Girona, A.;Mendy, D.;Ito, T.;Miller, K.;Gandhi, A. K.;Kang, J.;Karasawa, S.;Carmel, G.;Jackson, P.;Abbasian, M.;Mahmoudi, A.;Cathers, B.;Rychak, E.;Gaidarova, S.;Chen, R.;Schafer, P. H.;Handa, H.;Daniel, T. O.;Evans, J. F.;Chopra, R.
通讯作者: Chopra, R.